^
    7d
    Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Nationwide Children's Hospital | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial primary completion date
    |
    Lutathera (lutetium Lu 177 dotatate)
    7d
    LuTectomy: Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Peter MacCallum Cancer Centre, Australia | Trial completion date: Dec 2023 --> Aug 2025
    Trial completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    9d
    Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy. (clinicaltrials.gov)
    P1, N=65, Recruiting, University of Michigan Rogel Cancer Center | N=45 --> 65
    Enrollment change
    |
    TheraSphere (yttrium 90 microspheres)
    2ms
    Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia (clinicaltrials.gov)
    P=N/A, N=7, Terminated, Northwestern University | N=20 --> 7 | Trial completion date: Apr 2025 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2025 --> Apr 2024; Low enrollment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    2ms
    KinLET: Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ITM Solucin GmbH | Initiation date: Jun 2024 --> Sep 2024
    Trial initiation date
    |
    Solucin (177Lu-edotreotide)
    3ms
    MANDARIN (S6371) (clinicaltrials.gov)
    P3, N=92, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Dec 2025
    Enrollment closed • Trial primary completion date
    |
    cisplatin • TheraSphere (yttrium 90 microspheres)
    3ms
    START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (clinicaltrials.gov)
    P3, N=300, Recruiting, Lund University Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    SSTR (Somatostatin Receptor)
    |
    capecitabine • Solucin (177Lu-edotreotide)
    3ms
    DOORwaY90: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Sirtex Medical | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SIR-Spheres (yttrium-90 microspheres)
    3ms
    LUFOR: "Receptor Radionuclide Therapy With 177Lu-DOTATOC (clinicaltrials.gov)
    P2, N=100, Recruiting, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SSTR2 (Somatostatin Receptor 2)
    |
    Solucin (177Lu-edotreotide)
    4ms
    177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review. (PubMed, Q J Nucl Med Mol Imaging)
    The tumor AD that was reported during treatment with 177Lu-SSTR-RT in refractory meningioma patients is generally low. Harmonization of the methodology for dosimetry calculations is needed to compare the different reported values and optimize treatment at the individual level.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    4ms
    DOORwaY90: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Sirtex Medical | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    SIR-Spheres (yttrium-90 microspheres)
    4ms
    Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study. (PubMed, Oncologist)
    Careful patient selection, including consideration of the prognostic factors ECOG, baseline CEA, and KRAS status, sets outcome expectations in patients with colorectal liver metastases suitable for TARE/Chemo as second-line treatment (Trial Registry Number: NCT01483027).
    Journal • HEOR
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    TheraSphere (yttrium 90 microspheres)
    6ms
    Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial (clinicaltrials.gov)
    P1/2, N=25, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P1/2 trial
    |
    TheraSphere (yttrium 90 microspheres)
    6ms
    ROWAN: TheraSphere With Durvalumab and Tremelimumab for HCC (clinicaltrials.gov)
    P2, N=100, Recruiting, Boston Scientific Corporation | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab) • TheraSphere (yttrium 90 microspheres)
    6ms
    Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia (clinicaltrials.gov)
    P=N/A, N=20, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TheraSphere (yttrium 90 microspheres)
    6ms
    VOYAGER: First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (clinicaltrials.gov)
    P=N/A, N=36, Suspended, Boston Scientific Corporation | Recruiting --> Suspended
    Trial suspension
    |
    TheraSphere (yttrium 90 microspheres)
    7ms
    LUCIDA_2: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, FutureChem | Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    [177Lu]ludotadipep (177 Lu-FC705)
    7ms
    LUCIDA: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application (clinicaltrials.gov)
    P1/2, N=26, Recruiting, FutureChem | Phase classification: P2a --> P1/2 | Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    FOLH1 positive
    |
    [177Lu]ludotadipep (177 Lu-FC705)
    7ms
    TACOME: Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver (clinicaltrials.gov)
    P=N/A, N=202, Completed, Ankara University | Not yet recruiting --> Completed | N=350 --> 202 | Initiation date: Sep 2023 --> Jan 2024
    Trial completion • Enrollment change • Trial initiation date
    |
    TheraSphere (yttrium 90 microspheres)
    7ms
    FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)
    P1, N=12, Recruiting, Boston Scientific Corporation | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    8ms
    Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    SIR-Spheres (yttrium-90 microspheres)
    8ms
    STRATUM: Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients (clinicaltrials.gov)
    P2, N=176, Recruiting, National Cancer Centre, Singapore | Trial completion date: Nov 2025 --> Oct 2026 | Trial primary completion date: Jan 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • SIR-Spheres (yttrium-90 microspheres)
    9ms
    Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection (clinicaltrials.gov)
    P1, N=2, Terminated, Northwestern University | Trial completion date: Dec 2022 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Oct 2023; Lack of funding
    Trial completion date • Trial termination • Trial primary completion date
    |
    Opdivo (nivolumab) • TheraSphere (yttrium 90 microspheres)
    10ms
    VOYAGER: First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (clinicaltrials.gov)
    P=N/A, N=36, Recruiting, Boston Scientific Corporation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TheraSphere (yttrium 90 microspheres)
    10ms
    PROACTIF: Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TheraSphere (yttrium 90 microspheres)
    10ms
    Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy (clinicaltrials.gov)
    P2, N=0, Withdrawn, Emory University | N=50 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    SIR-Spheres (yttrium-90 microspheres)
    10ms
    A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Ruimin Wang
    New P1 trial • Metastases
    10ms
    A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Xinlu Wang
    New P1 trial • Metastases
    10ms
    TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=0, Approved for marketing, University of California, Irvine | N=186 --> 0
    Enrollment change
    |
    AFP (Alpha-fetoprotein)
    |
    TheraSphere (yttrium 90 microspheres)
    10ms
    VOYAGER: First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (clinicaltrials.gov)
    P=N/A, N=36, Not yet recruiting, Boston Scientific Corporation
    New trial
    |
    TheraSphere (yttrium 90 microspheres)
    11ms
    REALM: 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Ochsner Health System
    Trial completion date • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    11ms
    FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)
    P1, N=12, Recruiting, Boston Scientific Corporation | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    11ms
    Ablative Radioembolisation for Locally Advanced Hepatocellular Carcinoma (RESOLVE) (clinicaltrials.gov)
    P2, N=30, Recruiting, Seoul National University Hospital
    New P2 trial
    |
    TheraSphere (yttrium 90 microspheres)
    12ms
    Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison. (PubMed, Eur J Cancer)
    In HCC patients receiving treatment, TARE using Y-90 resin microspheres may achieve comparable effectiveness outcomes compared with AB.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • SIR-Spheres (yttrium-90 microspheres)
    1year
    REALM: 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Ochsner Health System | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TheraSphere (yttrium 90 microspheres)
    1year
    MANDARIN (S6371) (clinicaltrials.gov)
    P3, N=90, Recruiting, Boston Scientific Corporation | Trial completion date: Apr 2026 --> Oct 2026 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    cisplatin • TheraSphere (yttrium 90 microspheres)
    1year
    TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. (clinicaltrials.gov)
    P=N/A, N=5, Completed, Boston Scientific Corporation | Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Jun 2023
    Trial completion • Trial completion date
    |
    TheraSphere (yttrium 90 microspheres)
    1year
    Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, GrandPharma (China) Co., Ltd.
    New trial • Metastases
    |
    SIR-Spheres (yttrium-90 microspheres)
    1year
    Y-90 MICROSPHERE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC) PATIENT-DERIVED TUMOROIDS AND CELL LINES REVEALS HETEROGENEITY OF RESPONSE (AASLD 2023)
    A panel of Human HCC cell lines (HepG2 and PLC/PRF/5 characterized by high expression of hepatocyte and liver progenitor genes, and SNU-449 and SNU-423, characterized by high expression of stem cell and epithelial-mesenchymal transition genes) and a selected tumoroid were treated at escalating activities (0-20 MBq/ml) of glass Y-90 microspheres (Therasphere, Boston Scientific) for 10 days in vitro... HCC cell lines and tumoroids demonstrate heterogenous sensitivity to Y-90 microsphere treatment in vitro, potentially reflected by underlying transcriptomic profiles. Establishing patient derived HCC tumoroids for in vitro Y-90 microsphere treatment screens is feasible and serves as a powerful platform to assess biological underpinnings of Y-90-RE response with the advantage of being linked to clinical metadata.
    Preclinical
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • AXIN1 (Axin 1)
    |
    TheraSphere (yttrium 90 microspheres)
    1year
    ROWAN: TheraSphere With Durvalumab and Tremelimumab for HCC (clinicaltrials.gov)
    P2, N=100, Recruiting, Boston Scientific Corporation | Trial completion date: Sep 2027 --> Jun 2027 | Trial primary completion date: Jul 2027 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab) • TheraSphere (yttrium 90 microspheres)
    over1year
    REALM: 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Ochsner Health System
    New trial
    |
    TheraSphere (yttrium 90 microspheres)
    over1year
    ROWAN: TheraSphere With Durvalumab and Tremelimumab for HCC (clinicaltrials.gov)
    P2, N=100, Recruiting, Boston Scientific Corporation | Suspended --> Recruiting | N=150 --> 100 | Trial primary completion date: Mar 2027 --> Jul 2027
    Enrollment open • Enrollment change • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab) • TheraSphere (yttrium 90 microspheres)